Outcomes of phenylketonuria with relevance to follow-up

Journal of Inherited Metabolic Disease

Volumn 1, Issue , 2011, Pages 49-55

  van Spronsen, F J ^a   Belanger Quintana A ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Follow up; Guidelines; Neurocognitive outcome; Nutritional deficiencies; Phenylalanine; Phenylketonuria

Indexed keywords

EID: 84920881995     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/8904_2011_16     Document Type: Article

References (45)

1. AbadieV, BerthelotJ, FeilletFet al(2005)Association franc¸aise pourle de´pistage et la prevention des handicaps de l’enfant (AFDPHE).Arch Pediatr12:594–601
2. AlbrechtJ, GarbadeSF, BurgardP(2009)Neuropsychological speedtests and blood phenylalanine levels in patients with phenylketonuria:a meta-analysis. NeurosciBiobehav Rev33:414–421
3. AmbroszkiewiczJ, GajewskaJ, Laskowska-KlitaT(2004)A study ofbone turnover markers in prepubertal children with phenylketonuria.Eur J Pediatr163:177–178
4. AnastasoaieV, KurziusL, ForbesP, WaisbrenS(2008)Stability ofblood phenylalanine levels and IQ in children with phenylketonuria.Mol Genet Metab95:17–20
5. BlauN, Belanger-QuintanaA, DemirkolMet al(2009)Optimizing theuse of sapropterin (BH4) in the management of phenylketonuria.Mol Genet Metab96:158–163
6. BlauN, van SpronsenFJ, LevyHL(2010)Phenylketonuria. Lancet376:1417–1427
7. BoschAM, TyboutW, van SpronsenFJ, de ValkHW, WijburgFA,GrootenhuisMA(2007)The course of life and quality of life ofearly and continuously treated Dutch patients with phenylketonuria.J Inherit Metab Dis30:29–34
8. CamfieldCS, JosephM, HurleyT, CampbellK, SandersonS, CamfieldPR(2004)Optimal management of phenylketonuria: a centralizedexpert team is more successful than a decentralized model of care.J Pediatr145:53–57
9. CroneMR, van SpronsenFJ, OudshoornK, BekhofJ, van RijnG,VerkerkPH(2005)Behavioural factors related to metabolic controlin patients with phenylketonuria. J Inherit Metab Dis28:627–637
10. FaderlS, O’BrienS, PuiCHet al(2010)Adult acute lymphoblasticleukemia: concepts and strategies. Cancer116:1165–1176
11. FeilletF, AgostiniC(2010)Nutritional issues in treating phenylketonuria.J Inherit Metab Dis33:659–664, Epub Feb 2010
12. FeilletF, van SpronsenFJ, MacdonaldAet al(2010)Challenges andpitfalls in themanagement of phenylketonuria. Pediatrics126:233–241
13. FekkesM, TheunissenNC, BrugmanEet al(2000)Development andpsychometric evaluation of the TAPQOL: a health-related quality oflife instrument for 1-5-year-old children. Qual Life Res9:961–972
14. FeldmannR, DeneckeJ, GrenzebachM, WeglageJ(2005)Frontallobe-dependent functions in treated phenylketonuria: blood phenylalanineconcentrations and long-term deficits in adolescents andyoung adults. J Inherit Metab Dis28:445–455
15. GassióR, ArtuchR, VilasecaMAet al(2005)Cognitive functionsin classic phenylketonuria and mild hyperphenylalaninaemia:experience in a paediatric population. Dev Med Child Neurol47:443–448
16. GrootenhuisMA, StamH, Destree-VonkA, HeijmansHSA, LastBF(2003)Levensloopvragenlijstvoorjong-volwassenen (Course of lifequestionnaire for Young adults). Gedrag en Gezondheid31:336–350
17. GuldbergP, ReyF, ZschockeJ, RomanoV, FrançoisB, MichielsLet al(1998)A European multicenter study of phenylalanine hydroxylasedeficiency: classification of 105 mutations and a general system forgenotype-based prediction of metabolic phenotype. Am J HumGenet63:71–79
18. HendrikxMM, van der SchotLW, SlijperFM, HuismanJ, KalverboerAF(1994)Phenylketonuria and some aspects of emotional development.Eur J Pediatr153:832–835
19. HoeksmaM, ReijngoudDJ, PruimJ, de ValkHW, PaansAM, vanSpronsenFJ(2009)Phenylketonuria: high plasma phenylalaninedecreases cerebral protein synthesis. Mol Genet Metab96:177–182
20. HuijbregtsSC, de SonnevilleLM, LichtR, van SpronsenFJ, VerkerkPH, SergeantJA(2002)Sustained attention and inhibition ofcognitive interference in treated phenylketonuria: associationswith concurrent and lifetime phenylalanine concentrations. Neuropsychologia40:7–15
21. KayaalpE, TreacyE, WatersPJ, ByckS, NowackiP, ScriverCR(1997)Human phenylalanine hydroxylase mutations and hyperphenylalaninemiaphenotypes: a metanalysis of genotype-phenotypecorrelations. Am J Hum Genet61:1309–1317
22. Medical Research Council for Phenylketonuria(1993)Recommendationson the dietary management of phenylketonuria. Report ofMedical Research Council Working Party on phenylketonuria.Arch Dis Child68:426–427
23. MilletP, VilasecaMA, VallsCet al(2005)Isdeoxypyridinoline a goodresorptionmarkerto detect osteopenia in phenylketonuria?ClinBiochem38:1127–1132
24. PietzJ, FätkenheuerB, BurgardP, ArmbrusterM, EsserG, SchmidtH(1997)Psychiatric disorders in adult patients with early-treatedphenylketonuria. Pediatrics99:345–350
25. PietzJ, RuppA, BurgardP, BoeschC, KreisR(2002)No evidence forindividual blood-brain barrier phenylalanine transport to influenceclinical outcome in typical phenylketonuria patients. Ann Neurol52:382–383
26. PittDB, DanksDM(1991)The natural history of untreated phenylketonuriaover 20 years. J Paediatr Child Health27:189–190
27. RisMD, WilliamsSE, HuntMM, BerryHK, LeslieN(1994)Earlytreatedphenylketonuria:adultneuropsychologic outcome. J Pediatr124:388–392
28. ScriverCR(2007)The PAH gene, phenylketonuria, and a paradigmshift.Hum Mutat28:831–845
29. ScriverCR, KaufmanS(2001)Hyperphenylalaninemia: phenylalaninehydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, ValleD, Childs B, Vogelstein B (eds) Themetabolicandmolecular bases ofinherited disease, 8th edn. McGraw-Hill, New York, pp1667–1724
30. ScriverCR, WatersPJ(1999)Monogenic traits are not simple: lessonsfrom phenylketonuria. Trends Genet15:267–272
31. SimonE, SchwarzM, RoosJet al(2008)Evaluation of quality of lifeand description of the sociodemographic state in adolescent andyoung adult patients with phenylketonuria (PKU).Health Qual LifeOutcomes26:25
32. SirtoriLR, Dutra-FilhoCSet al(2005)Oxidative stress in patients withphenylketonuria. BiochimBiophysActa1740:68–73
33. SullivanJE, ChangP(1999)Review: emotional and behavioural functioningin phenylketonuria. J PediatrPsychol24:281–299
34. vanSpronsenFJ, BurgardP(2008)The truth of treating patientswith phenylketonuria after childhood: the need for a new guideline.J Inherit Metab Dis31:673–679
35. vanSpronsenFJ, van RijnM, DorgeloBet al(2009a)Phenylalaninetolerance can already reliably be assessed at the age of 2 years inpatients with PKU. J Inherit Metab Dis32:27–31
36. vanSpronsenFJ, AhringKK, GizewskaM(2009b)PKU – What isdaily practice in various centres in Europe?J Inherit Metab Dis32:58–64
37. vanSpronsenFJ, HoeksmaM, ReijngoudDJ(2009c)Brain dysfunctionin phenylketonuria: is phenylalanine toxicity the only possiblecause?J Inherit Metab Dis32:46–51
38. VugteveenI, HoeksmaM, BjorkeMonsemALet al(2010)Serumvitamin B12 concentrations within reference values do not excludefunctional vitamin B12 deficiency in PKU patients of various ages.Mol Genet Metab102:13–17, Epub October 2010
39. WaisbrenSE, LevyHL(1991)Agoraphobia in phenylketonuria.J Inherit Metab Dis14:755–764
40. WaisbrenS, WhiteDA(2010)Screening for cognitive and socialemotionalproblems in individuals with PKU: tools for use in themetabolic clinic.Mol Genet Metab99(Suppl 1):S96–S99
41. WaisbrenSE, BrownMJ, de SonnevilleLM, LevyHL(1994)Reviewof neuropsychological functioning in treated phenylketonuria: aninformation processing approach. ActaPaediatr407:98–103
42. WaisbrenSE, NoelK, FahrbachKet al(2007)Phenylalanine bloodlevels and clinical outcomes in phenylketonuria: a systematic literaturereview and meta-analysis. Mol Genet Metab92:63–70
43. WeglageJ, FündersB, WilkenBet al(1992)Psychological and socialfindings in adolescents with phenylketonuria. Eur J Pediatr151:522–525
44. WeglageJ, RuppA, SchmidtE(1994)Personality characteristics inpatients with phenylketonuria treated early. Pediatr Res35:611–613
45. WeglageJ, WiedermannD, DeneckeJet al(2001)Individual bloodbrainbarrier phenylalanine transport determines clinical outcome inphenylketonuria. Ann Neurol50(463):467